<DOC>
	<DOCNO>NCT02722057</DOCNO>
	<brief_summary>The purpose study confirm long-term safety effectiveness Kalydeco® ( ivacaftor ) US CF patient R117H-CFTR mutation &lt; 18 year age describe long-term safety effectiveness Kalydeco CF patient R117H-CFTR mutation overall patient ≥18 year . The long-term safety effectiveness Kalydeco examine totality evaluation primary outcome measure .</brief_summary>
	<brief_title>A Study Confirm Long-term Safety Effectiveness Kalydeco Patients With Cystic Fibrosis Who Have R117H-CFTR Mutation , Including Pediatric Patients</brief_title>
	<detailed_description>Patient follow-up ( i.e. , collection outcome data treatment initiation ) Non-Interventional Cohort least 36 month . The study also include retrieval retrospective data enter registry 36 month initiation Kalydeco treatment , patient match Interventional Non-Interventional Cohorts . This permit within-group comparison outcome Kalydeco treatment effectiveness safety .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Interventional Cohort Male female confirm diagnosis CF Must least 1 allele R117HCFTR mutation Enrolled US CFF Patient Registry time entry study Patients 6 &lt; 18 year age date sign ICF , appropriate , date assent If sexually active , male patient father child female patient childbearing potential must agree meet contraception requirement Non Interventional Cohort Male female confirm diagnosis CF Must least 1 allele R117HCFTR mutation Enrolled US CFF Patient Registry With record Kalydeco treatment initiation 01 January 2015 31 December 2016 Historical Cohort Patients CF CFF Patient Registry 01 January 2009 Must least 1 allele R117HCFTR mutation Patients evidence prior Kalydeco exposure Interventional Cohort History illness condition , opinion investigator , might confound result study pose additional risk administer study drug subject Pregnant , plan pregnancy , breastfeeding , willing follow contraception requirement Abnormal liver function enrollment Abnormal renal function enrollment History solid organ hematological transplantation Ongoing participation another therapeutic clinical study prior participation investigational drug study within 30 day Enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>